Vincristine News and Research

Vincristine is the active ingredient in a drug used to treat acute leukemia. It is used in combination with other drugs to treat Hodgkin disease, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumor. Vincristine is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division. It is a type of vinca alkaloid and a type of antimitotic agent.

Scientists receive nearly $3 million from NIH to uncover how plants make medicinal compounds

6. November 2009 01:53

Scientists at Michigan State University are receiving nearly $3 million from the National Institutes of Health to uncover how several popular plants make medicinal compounds. [More]

29c0dadb-ec17-4804-8fe4-a1e368549c09|0|.0

Posted in: Medical Science News | Medical Research News

Tags: Biochemistry, Cancer, DNA, Education, Vinblastine, Vincristine

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

22. October 2009 05:22

Cell Therapeutics, Inc. announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission (CR) in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma (NHL) patients. [More]

74b248a8-f0d4-4193-b507-b88acce24c57|1|5.0

Posted in: Drug Trial News | Medical Condition News

Tags: Anemia, Anthracycline, Breast Cancer, Cancer, Catheter, Cell, Chemotherapy, Congestive Heart Failure, Cough, Cyclophosphamide, Doxorubicin, Heart Failure, Hodgkin's Lymphoma, Hospital, Leukemia, Lymphoma, Neutropenia, Non-Hodgkin's Lymphoma, Oncology, Prescription Drug, Rituximab, Thrombocytopenia, Vincristine

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

22. October 2009 01:40

Millennium: The Takeda Oncology Company today announced the initiation of a Phase II clinical trial examining rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without VELCADE® (bortezomib) for Injection for patients with a common type of lymphoma. The study will examine previously untreated patients with a genomically defined subtype of lymphoma called non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma. [More]

f4f541c0-5bc7-444a-abff-37b6118c369f|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Abdominal Pain, Anemia, Anorexia, Anxiety, Arthralgia, Blindness, Bone, Cell, Constipation, Cough, Cyclophosphamide, Dehydration, Diarrhea, Doxorubicin, Dyspnea, Edema, Headache, Heart Failure, Herpes, Herpes Zoster, Hypersensitivity, Insomnia, Liposome, Lymphoma, Multiple Myeloma, Nausea, Neuropathy, Neutropenia, Nursing, Oncology, Pneumonia, Rituximab, Thrombocytopenia, Vincristine, Vomiting

Rituxan's sBLA receives a Complete Response from the FDA

19. October 2009 05:04

Genentech, Inc. a wholly-owned member of the Roche Group, and Biogen Idec announced today that the companies received a Complete Response from the U.S. Food and Drug Administration (FDA) for a supplemental Biologics License Application (sBLA) for Rituxan (rituximab) plus methotrexate (MTX) in patients with moderately-to-severely active rheumatoid arthritis (RA) who no longer respond to treatment with a disease modifying antirheumatic drug (DMARD), including MTX. [More]

dbcf2e2c-47f1-42eb-8f11-d148823f81ed|0|.0

Posted in: Pharmaceutical News

Tags: Anthracycline, Antibody, Arthritis, Biotechnology, Bone, Bone Marrow, Brain, Cell, Chemotherapy, Cough, Cyclophosphamide, Doxorubicin, Headache, Hepatitis B, Immunology, Lymphoma, MabThera, Methotrexate, Nausea, Oncology, Rheumatoid Arthritis, Rheumatology, Rituximab, Vincristine, Virus

Research study reveals primary chemotherapy benefits

3. October 2009 02:50

Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone. [More]

3794ba19-b097-450f-98ba-aae209ce8583|0|.0

Posted in: Device / Technology News | Medical Condition News

Tags: Brain, Brain Tumor, Cancer, Chemotherapy, Glioma, Hospital, Neurology, Oncology, Pathology, Radiation Therapy, Radiotherapy, Temozolomide, Vincristine

Obesity can increase cancer incidence in leukemic children

23. September 2009 00:30

Obesity is an important factor contributing to chemotherapy resistance and increasing relapse rates among children with leukemia, according to recent findings published online first in Cancer Research, a journal of the American Association for Cancer Research. [More]

e6252c25-31d7-4fdd-8d86-920753e3b0d3|2|3.0

Posted in: Child Health News | Medical Condition News

Tags: Bone, Bone Marrow, Cancer, Chemotherapy, Endocrinology, Hematology, Hospital, Leukemia, Obesity, Oncology, Pediatrics, Physiology, Vincristine

Genentech releases Phase III PRIMA study findings

17. September 2009 02:14

Genentech, Inc., a wholly-owned member of the Roche Group and Biogen Idec, today announced that a Phase III study (PRIMA) showed that patients with follicular lymphoma who continued receiving Rituxan (rituximab) alone after responding to Rituxan and chemotherapy lived longer without their disease worsening (progression-free survival or PFS) than those who did not continue to receive Rituxan. [More]

dba38df9-3932-485e-b0ae-917e837bd21d|0|.0

Posted in: Drug Trial News | Pharmaceutical News

Tags: Anthracycline, Antibody, Arthritis, Biotechnology, Bone, Bone Marrow, Brain, Cell, Chemotherapy, Cough, Cyclophosphamide, Doxorubicin, Follicular Lymphoma, Headache, Hepatitis B, Immunology, Lymphoma, MabThera, Methotrexate, Nausea, Neurology, Oncology, Rheumatoid Arthritis, Rituximab, Vincristine, Virus

Genentech and Biogen Idec submit applications to FDA for Rituxan in chronic lymphocytic leukemia

20. May 2009 02:16

Genentech, Inc. and Biogen Idec today announced that the companies submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Rituxan (rituximab) plus standard chemotherapy for people with previously untreated or treated chronic lymphocytic leukemia (CLL). [More]

bfc0fb0d-f3d9-40d2-ad2f-3fc316dfd58d|0|.0

Posted in: Pharmaceutical News

Tags: Antibody, Arthritis, Biologics Drug / Agent, Chronic Lymphocytic Leukemia, Hepatitis B, MabThera, Neutropenia, Rituximab, TNF Blockers, Vincristine

Blocking the dual leucine zipper kinase gene may help ease painful nerve condition

15. March 2009 22:57

Scientists have identified the first gene that pulls the plug on ailing nerve cell branches from within the nerve cell, possibly helping to trigger the painful condition known as neuropathy. [More]

90e47d9f-7a4f-4379-8ee4-e0fb684bd3bf|0|.0

Posted in: Medical Research News

Tags: Cancer, Chemotherapy, Diabetes, Genetics, Glaucoma, Nervous System, Neurodegeneration, Neurology, Neuropathy, Neuroscience, Parkinson's Disease, Stress, Stress Related, Stroke, Vincristine

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

11. March 2009 23:13

Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks. [More]

c6f12d86-7c4a-4a86-a343-ddaf5070bf94|1|5.0

Posted in: Drug Trial News

Tags: Anthracycline, Antibody, Autoimmune Disease, Blood Pressure, Bone, Bone Marrow, Brain, Chemotherapy, Corticosteroid, Cough, Cyclophosphamide, Doxorubicin, Edema, Hepatitis B, Hodgkin's Lymphoma, Immunology, Leukopenia, Lupus, Lymphoma, MabThera, Nausea, Neutropenia, Non-Hodgkin's Lymphoma, Rituximab, Systemic Lupus Erythematosus, TNF Blockers, Vasculitis, Vincristine, Virus

Rituximab useful for advanced indolent lymphoma

11. March 2009 03:05

A new study has found for the first time that maintenance therapy with the novel antibody, rituximab (MR) following cyclophosphamide, vincristine and prednisone (CVP) therapy improves progression-free survival in patients with stage III-IV indolent lymphoma, according to Howard S. Hochster, M.D. of NYU Langone Medical Center, lead author of a recent study published online ahead of print in the Journal of Clinical Oncology. [More]

d4cdcd80-dc8a-4f76-9795-7de57b18353a|0|.0

Posted in: Drug Trial News

Tags: Antibody, Cancer, Chemotherapy, Cyclophosphamide, Follicular Lymphoma, Lymphoma, Oncology, Pharmacology, Rituximab, Vincristine

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

8. December 2008 13:39

Genentech, Inc. and Biogen Idec have announced that two global Phase III studies in chronic lymphocytic leukemia (CLL), CLL8 and REACH, showed Rituxan (rituximab) plus chemotherapy significantly increased the time patients lived without their disease advancing, as defined by the primary endpoint of progression-free survival (PFS), when compared to chemotherapy alone. [More]

3c11ef44-d7aa-44df-84c0-6a41c61a4b64|0|.0

Posted in: Drug Trial News

Tags: Anthracycline, Antibody, Arthralgia, Arthritis, Biologics Drug / Agent, Bone, Bone Marrow, Cancer, Chemotherapy, Chronic Lymphocytic Leukemia, Cyclophosphamide, Doxorubicin, Genetics, Hematology, Hepatitis B, Hodgkin's Lymphoma, Hypertension (High Blood Pressure), Immunotherapy, Lymphoma, Lymphopenia, MabThera, Methotrexate, Nausea, Neutropenia, Non-Hodgkin's Lymphoma, Oncology, Rheumatoid Arthritis, Rituximab, TNF Blockers, Vincristine

Vitamin C supplements appear to undercut the effectiveness of cancer drugs

1. October 2008 22:26

A new study by scientists in the United States has revealed that vitamin C may blunt the effectiveness of chemotherapy treatment. [More]

b771a50b-f2e1-477a-bc51-d22126fd6ba4|0|.0

Posted in: Medical Research News

Tags: Antioxidant, Cancer, Chemotherapy, Cisplatin, Diet, Doxorubicin, Gleevec, Imatinib Mesylate, Methotrexate, Vincristine, Vitamin C, Vitamin E, Vitamin K

New hope for children with bilateral Wilms tumors

25. March 2008 02:26

Physicians at St. Jude Children's Research Hospital have demonstrated that children with bilateral Wilms tumor, a cancer of the kidneys, can retain normal function in both kidneys by undergoing a procedure called bilateral nephron-sparing surgery, even when preoperative scans suggest that the tumors are inoperable. [More]

4ecac4e8-a8cb-45d0-adf9-acd90e31332c|0|.0

Posted in: Medical Condition News

Tags: Cancer, Chemotherapy, Dialysis, Doxorubicin, Human Anatomy, Pediatrics, Radiation Therapy, Renal Failure, Transplant, Vincristine, Wilms Tumor

Cannabis compound may stop breast cancer spreading

20. November 2007 23:25

American researchers have found that a compound found in cannabis may stop breast cancer spreading throughout the body. [More]

df1aba03-8eb3-497c-b88d-6bda6043f69e|1|4.0

Posted in: Medical Research News

Tags: Brain, Breast Cancer, Cancer, Chemotherapy, Genetics, Lung Cancer, Marijuana/Cannabis, Metastasis, Smoking, Smoking Addiction, Vincristine

<< Previous posts

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

Free!

Recent Comments

Twitter

Information

Vincristine News and Research

Scientists receive nearly $3 million from NIH to uncover how plants make medicinal compounds

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

Rituxan's sBLA receives a Complete Response from the FDA

Research study reveals primary chemotherapy benefits

Obesity can increase cancer incidence in leukemic children

Genentech releases Phase III PRIMA study findings

Genentech and Biogen Idec submit applications to FDA for Rituxan in chronic lymphocytic leukemia

Blocking the dual leucine zipper kinase gene may help ease painful nerve condition

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Rituximab useful for advanced indolent lymphoma

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Vitamin C supplements appear to undercut the effectiveness of cancer drugs

New hope for children with bilateral Wilms tumors

Cannabis compound may stop breast cancer spreading

Recent Articles

Free!

Recent Comments

Twitter

Information

Vincristine News and Research

Medical News Cloud

Recent Articles